



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care fo

No. 07-32

July 27, 2007

Eisai Co., Ltd.

**Eisai Enters into In-licensing Agreement with Sepracor
for Eszopiclone Insomnia Treatment**

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Sepracor Inc. (Headquarters: Massachusetts, the U.S., President and CEO: Adrian Adams) signed an in-licensing agreement for the insomnia treatment eszopiclone (product name in the U.S.: LUNESTA[®]) on July 26, 2007 (the U.S. eastern time). In this agreement, Eisai will assume exclusive rights for development and marketing of this compound in Japan.

Eszopiclone is a non-benzodiazepine type allosteric GABA agonist discovered by Sepracor. With its short-acting feature that allows fewer interruptions during sleep, the compound may help patients with transient insomnia as well as chronic insomnia in the elderly. Furthermore, in clinical studies conducted in the U.S., the compound was well-tolerated and had a low risk

<Note to Editor>

Company Profile of Sepracor Inc.

Headquarters: Marlborough, Massachusetts, the United States

Establishment: 1984

Number of Employees: 2,600

Company website: www.sepracor.com

###